With cost of private drug plan claims rising about 5.5 per cent each year, pooling is one solution that could be beneficial for benefits plan sponsors. “Theoretically, if these claims could be shared across a broader group, such as the complete private insurance industry, plan costs could be less volatile for individual plan sponsors,” said […]
Plan sponsors face challenges balancing benefits plan sustainability while also ensuring their plan members have access to the care they need, said Marie-Hélène Dugal, manager of pharmacy benefit strategy at Medavie Blue Cross, during a session at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December. Referring to Medavie’s claims data, […]
Attention deficit hyperactivity disorder is commonly misunderstood and can reduce the ability of a person to function while impacting their quality of life, said Anjila Arora, director of pharmaceutical benefits at Sun Life Financial Inc., during a session at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December. Although ADHD […]
As pharmacists’ scope of practice evolves across the country, their expanded role in drug plan management can improve plan member health and positively impact plan sponsors’ bottom lines. Challenges in the Canadian health-care system — such as the millions of people who don’t have access to a family doctor, extended emergency rooms wait times or […]
With the cost of drug claims continuing to rise in 2021, benefits plan sponsors can enable certain drug programs to curb costs, keeping their plans sustainable and offering the benefits that members highly value, said Lavina Viegas, director of pharmacy operations at Telus Health, during a session at Benefits Canada’s 2022 Face to Face Drug […]
While a transplant can be life-altering for a patient as a permanent cure for their underlying condition, it can also profoundly affect their immune system, according to Dr. Matthew Cheng, assistant professor in transplant infectious diseases and medical mycology at McGill University, speaking during a panel discussion at Benefits Canada’s Face to Face Drug Plan […]
About a million Canadians are impacted by rare diseases, which disproportionately affect younger patients — 70 per cent start in childhood and, sadly, half of these children won’t reach adulthood, said Suzanne Lepage, a private health plan strategist, during a session supported by Alexion Pharmaceuticals at Benefits Canada‘s 2022 Face to Face Drug Plan Management Forum […]
While vaccine coverage varies across provincial drug plans, several million Canadians who are members of private drug plans don’t have coverage at all, according to Chris Bonnett (pictured left), founder and principal consultant of H3 Consulting, during a panel session supported by GSK, Merck & Co. Inc. and Pfizer Canada Inc. at Benefits Canada’s 2022 […]
Living with a rare chronic disease while also managing an employer-sponsored benefits plan provides Chris MacLeod with a unique perspective. During a session supported by Vertex Pharmaceuticals at Benefits Canada’s 2022 Face to Face Drug Plan Management Forum in Toronto in December, MacLeod, the founding partner at Cambridge LLP, said he was diagnosed with cystic fibrosis […]
Approximately three million Canadians live with asthma, a chronic inflammatory disease that affects airways, limits airflow and makes breathing difficult, said Dr. Erika Penz, associate professor in respirology, critical care and sleep medicine at the University of Saskatchewan, during a webinar hosted by Benefits Canada and sponsored by GSK in November. Asthma, which affects people of […]